Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents

被引:68
作者
Moriyama, H
Tsukida, T
Inoue, Y
Yokota, K
Yoshino, K
Kondo, H
Miura, N
Nishimura, S
机构
[1] Japan Bioind Assoc, Hokkaido Collaborat Ctr, Kita Ku, Sapporo, Hokkaido 0010021, Japan
[2] Nippon Organon KK, R&D Labs, Miyakojima Ku, Osaka 5340016, Japan
[3] Hokkaido Univ, Div Biol Sci, Grad Sch Sci, Kita Ku, Sapporo, Hokkaido 0010021, Japan
关键词
D O I
10.1021/jm0304313
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
As a part of synthetic studies on MMP (matrix metalloproteinase)/ADAM (a disintegrin and metalloproteinase) inhibitors, we have preliminarily communicated that azasugar-based compound la exhibited a potential inhibitory activity on some metalloprotease-catalyzed proteolytic reactions. To find promising candidates for the topical treatment of psoriasis, we investigated stability in aqueous solution of compound la and its derivative 1b and then optimized the P1' substuent (2-5). In the present study, we synthesized novel derivatives of compound-la and evaluated their inhibitory activity toward MMP-1, -3, and -9, TACE, and HB-EGF shedding, from a viewpoint of versatility of azasugars as a functional scaffold. As a result, it was found that compound 1b demonstrated desirable inhibitory activity as an antipsoriatic agent, and some of the derivatives showed selective inhibitory activity. In addition, it was found that compound 1b exhibited a significant therapeutic effect on a mouse TPA-induced epidermal hyperplasia. model. Therefore, compound 1b could become a promising candidate as a practical antipsoriatic agent.
引用
收藏
页码:1930 / 1938
页数:9
相关论文
共 30 条
[1]   Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors [J].
Almstead, NG ;
Bradley, RS ;
Pikul, S ;
De, B ;
Natchus, MG ;
Taiwo, YO ;
Gu, F ;
Williams, LE ;
Hynd, BA ;
Janusz, MJ ;
Dunaway, CM ;
Mieling, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) :4547-4562
[2]   Protein ectodomain shedding [J].
Arribas, J ;
Borroto, A .
CHEMICAL REVIEWS, 2002, 102 (12) :4627-4637
[3]   Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].
Asakura, M ;
Kitakaze, M ;
Takashima, S ;
Liao, Y ;
Ishikura, F ;
Yoshinaka, T ;
Ohmoto, H ;
Node, K ;
Yoshino, K ;
Ishiguro, H ;
Asanuma, H ;
Sanada, S ;
Matsumura, Y ;
Takeda, H ;
Beppu, S ;
Tada, M ;
Hori, M ;
Higashiyama, S .
NATURE MEDICINE, 2002, 8 (01) :35-40
[4]   Therapeutic strategies for psoriasis [J].
Ashcroft, DM ;
Po, ALW ;
Griffiths, CEM .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (01) :1-10
[5]  
CHENG M, 1999, J MED CHEM, V42, P2
[6]  
COOK PW, 1997, J CLIN INVEST, V100, P2886
[7]   A NEW SYNTHESIS OF N-ACETYLNEURAMINIC ACID [J].
CSUK, R ;
HUGENER, M ;
VASELLA, A .
HELVETICA CHIMICA ACTA, 1988, 71 (03) :609-618
[8]  
DAVIDSON AN, 1998, Patent No. 9847494
[9]   A HEPARIN-BINDING GROWTH-FACTOR SECRETED BY MACROPHAGE-LIKE CELLS THAT IS RELATED TO EGF [J].
HIGASHIYAMA, S ;
ABRAHAM, JA ;
MILLER, J ;
FIDDES, JC ;
KLAGSBRUN, M .
SCIENCE, 1991, 251 (4996) :936-939
[10]   Matrix metalloproteinase inhibitors reduce phorbol ester-induced cutaneous inflammation and hyperplasia [J].
Holleran, WM ;
Galardy, RE ;
Gao, WN ;
Levy, D ;
Tang, PC ;
Elias, PM .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1997, 289 (03) :138-144